Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel reported Q2 2026 revenue of $0.6 million, down from $17.3 million in the prior year due to the absence of a one-time IP sale, and posted a net loss of $3.7 million or $1.13 per share. The pivotal Phase 3 trial of SGT-610 for Gorlin syndrome remains on track for top-line results in late November 2026, with management highlighting a lower-than-expected dropout rate of 9%.
Key figures
- Revenue
- $0.6 million
- Cash runway
- Q1 2028
- Dropout rate
- 9%
- Cash position total
- $49.3 million
- Phase3 readout timeline
- late November 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.